Antigenicity assessment of SARS-CoV-2 saltation variant BA.2.87.1

Emerg Microbes Infect. 2024 Dec;13(1):2343909. doi: 10.1080/22221751.2024.2343909. Epub 2024 May 2.

Abstract

The recent emergence of a SARS-CoV-2 saltation variant, BA.2.87.1, which features 65 spike mutations relative to BA.2, has attracted worldwide attention. In this study, we elucidate the antigenic characteristics and immune evasion capability of BA.2.87.1. Our findings reveal that BA.2.87.1 is more susceptible to XBB-induced humoral immunity compared to JN.1. Notably, BA.2.87.1 lacks critical escaping mutations in the receptor binding domain (RBD) thus allowing various classes of neutralizing antibodies (NAbs) that were escaped by XBB or BA.2.86 subvariants to neutralize BA.2.87.1, although the deletions in the N-terminal domain (NTD), specifically 15-23del and 136-146del, compensate for the resistance to humoral immunity. Interestingly, several neutralizing antibody drugs have been found to restore their efficacy against BA.2.87.1, including SA58, REGN-10933 and COV2-2196. Hence, our results suggest that BA.2.87.1 may not become widespread until it acquires multiple RBD mutations to achieve sufficient immune evasion comparable to that of JN.1.

Keywords: SARS-CoV-2; humoral immunity; immune escape; neutralizing antibodies; saltation variant.

MeSH terms

  • Animals
  • Antibodies, Neutralizing* / immunology
  • Antibodies, Viral* / immunology
  • Antigens, Viral / genetics
  • Antigens, Viral / immunology
  • COVID-19* / immunology
  • COVID-19* / virology
  • Humans
  • Immune Evasion*
  • Immunity, Humoral
  • Mutation
  • SARS-CoV-2* / genetics
  • SARS-CoV-2* / immunology
  • Spike Glycoprotein, Coronavirus* / genetics
  • Spike Glycoprotein, Coronavirus* / immunology

Substances

  • Antibodies, Neutralizing
  • Spike Glycoprotein, Coronavirus
  • Antibodies, Viral
  • spike protein, SARS-CoV-2
  • Antigens, Viral

Supplementary concepts

  • SARS-CoV-2 variants